GlassScriptPhysician profile
Rhea J Williams
NPI 1861612657
$2,511.36
in general payments reported to CMS, 2019-2025
13 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $588 · 2023: $591 · 2024: $611 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $689.17 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $346.10 | 2022-2023 | |
| Gilead Sciences, INC. | $248.01 | 2023 | Epclusa |
| Neurocrine Biosciences, INC. | $135.49 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $130.38 | 2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $129.38 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $125.12 | 2025 | Rezdiffra |
| Novo Nordisk INC | $123.84 | 2021 | |
| Qol Medical, LLC | $123.73 | 2024 | Sucraid |
| Otsuka America Pharmaceutical, INC. | $117.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $115.32 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $112.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhea Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.